Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
111 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Community Acquired Pneumonia - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Community Acquired Pneumonia - Pipeline Review, H2 2016', provides an overview of the Community Acquired Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia - The report reviews pipeline therapeutics for Community Acquired Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Community Acquired Pneumonia therapeutics and enlists all their major and minor projects - The report assesses Community Acquired Pneumonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Community Acquired Pneumonia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Community Acquired Pneumonia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Community Acquired Pneumonia Overview 9 Therapeutics Development 10 Pipeline Products for Community Acquired Pneumonia - Overview 10 Community Acquired Pneumonia - Therapeutics under Development by Companies 11 Community Acquired Pneumonia - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Community Acquired Pneumonia - Products under Development by Companies 15 Community Acquired Pneumonia - Companies Involved in Therapeutics Development 17 Aridis Pharmaceuticals LLC 17 BioAegis Therapeutics, Inc. 18 Biotest AG 19 C10 Pharma AS 20 InflaRx GmbH 21 ioGenetics, Inc. 22 Kyorin Pharmaceutical Co., Ltd. 23 Lascco SA 24 Melinta Therapeutics, Inc 25 Merck & Co., Inc. 26 Nabriva Therapeutics AG 27 Paratek Pharmaceuticals, Inc. 28 TaiGen Biotechnology Co., Ltd. 29 Takeda Pharmaceutical Company Limited 30 Tetraphase Pharmaceuticals Inc. 31 TiGenix NV 32 Community Acquired Pneumonia - Therapeutics Assessment 33 Assessment by Monotherapy Products 33 Assessment by Target 34 Assessment by Mechanism of Action 36 Assessment by Route of Administration 38 Assessment by Molecule Type 40 Drug Profiles 42 BT-086 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 C-10 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 CAL-02 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 ceftaroline fosamil - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Cx-611 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 DBAF-301 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 delafloxacin - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 IFX-1 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 KRPAM-1977X - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 KRPAM-1977Y - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 lefamulin acetate - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 nemonoxacin - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 omadacycline tosylate - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 PneumoMab - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 radezolid - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 Recombinant Plasma Gelsolin Replacement for Community Acquired Pneumonia - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 solithromycin - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 tosatoxumab - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 TP-271 - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 Community Acquired Pneumonia - Dormant Projects 97 Community Acquired Pneumonia - Discontinued Products 98 Community Acquired Pneumonia - Product Development Milestones 99 Featured News & Press Releases 99 Jun 28, 2016: Cempra Submits Marketing Authorization Application to EMA for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia 99 Jun 20, 2016: Nabriva Presents Data on Lefamulin at the American Society of Microbiology Microbe 2016 Conference 99 Jun 16, 2016: Cempra to Host Analyst and Investor Day on June 23, 2016 100 Jun 14, 2016: Melinta Therapeutics Presenting Results From Baxdela Programs At ASM Microbe 2016 Meeting 100 Jun 13, 2016: TaiGen Biotechnology Receives Market Approval from the China Food and Drug Administration for Taigexyn (nemonoxacin) 101 Jun 10, 2016: Cempra Announces Solithromycin Presentations at ASM Microbe 2016 Conference 101 May 31, 2016: Allergan Receives FDA Approval of TEFLARO (ceftaroline fosamil) for Pediatric Patients 102 May 25, 2016: Cempra Announces Successful Results in the Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted by Japanese Partner, Toyama Chemical (a subsidiary of FUJIFILM Holdings Corporation) 103 May 16, 2016: Nabriva Announces Lefamulin Presentation at ASM Microbe 2016 Conference 104 May 12, 2016: Cempra to Present Solithromycin IV Data at ATS 2016 105 May 01, 2016: Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia 105 Apr 11, 2016: Nabriva Initiates Second Phase 3 Clinical Trial of Lefamulin ("LEAP 2") in Patients with Community-Acquired Bacterial Pneumonia 106 Apr 04, 2016: Cempra to Present Data on Solithromycin at ECCMID 107 Feb 24, 2016: Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets 107 Feb 05, 2016: The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra Oral Solithromycin in Community-Acquired Bacterial Pneumonia 108 Appendix 110 Methodology 110 Coverage 110 Secondary Research 110 Primary Research 110 Expert Panel Validation 110 Contact Us 110 Disclaimer 111
List of Tables
Number of Products under Development for Community Acquired Pneumonia, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Development by Companies, H2 2016 (Contd..1) 16 Community Acquired Pneumonia - Pipeline by Aridis Pharmaceuticals LLC, H2 2016 17 Community Acquired Pneumonia - Pipeline by BioAegis Therapeutics, Inc., H2 2016 18 Community Acquired Pneumonia - Pipeline by Biotest AG, H2 2016 19 Community Acquired Pneumonia - Pipeline by C10 Pharma AS, H2 2016 20 Community Acquired Pneumonia - Pipeline by InflaRx GmbH, H2 2016 21 Community Acquired Pneumonia - Pipeline by ioGenetics, Inc., H2 2016 22 Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 23 Community Acquired Pneumonia - Pipeline by Lascco SA, H2 2016 24 Community Acquired Pneumonia - Pipeline by Melinta Therapeutics, Inc, H2 2016 25 Community Acquired Pneumonia - Pipeline by Merck & Co., Inc., H2 2016 26 Community Acquired Pneumonia - Pipeline by Nabriva Therapeutics AG, H2 2016 27 Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals, Inc., H2 2016 28 Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2016 29 Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 30 Community Acquired Pneumonia - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2016 31 Community Acquired Pneumonia - Pipeline by TiGenix NV, H2 2016 32 Assessment by Monotherapy Products, H2 2016 33 Number of Products by Stage and Target, H2 2016 35 Number of Products by Stage and Mechanism of Action, H2 2016 37 Number of Products by Stage and Route of Administration, H2 2016 39 Number of Products by Stage and Molecule Type, H2 2016 41 Community Acquired Pneumonia - Dormant Projects, H2 2016 97 Community Acquired Pneumonia - Discontinued Products, H2 2016 98
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.